提高疱疹性口炎治疗效率的途径

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL
R. Lutsenko, N. Moisieieva, A. Sydorenko, H.Yu. Ostrovska, A. A. Kapustianska
{"title":"提高疱疹性口炎治疗效率的途径","authors":"R. Lutsenko, N. Moisieieva, A. Sydorenko, H.Yu. Ostrovska, A. A. Kapustianska","doi":"10.26641/2307-0404.2023.2.283255","DOIUrl":null,"url":null,"abstract":"The treatment of herpetic stomatitis should be etiotropic, pathogenetic, symptomatic, and local. The research determined the effectiveness of inosine pranobex (1000 mg 4 times a day) in herpetic stomatitis treatment. Addition of inosine pranobex to the pharmacotherapy of herpetic stomatitis reduced hospital stay and duration of treatment. The drug suppresses the synthesis of the virus due to the structure of inosinic acid in the polyribosomes of the cell affected by the virus, and also helps to eliminate the deficiency or dysfunction of immunity that occurred in the case of herpetic stomatitis, it affects the activity of T-cytotoxic lymphocytes and natural killers, enhances the action of neutrophil granulocytes, chemotaxis and phagocytosis of monocytes and macrophages, increases the synthesis of interleukins IL-1 and IL-2, affects the number of Ig G immunoglobulins. Applying inosine pranobex also significantly decreased pain syndrome manifestations from the start of the treatment. It contributed to body temperature normalization 2 days earlier which shortened the treatment period at the in-patient department. Applying inosine pranobex in the combination therapy of herpetic stomatitis has shown a potent clinical efficacy and can be an alternatіve to acyclic nucleosides in patients with herpetic stomatitis of the oral mucosa.","PeriodicalId":41059,"journal":{"name":"Medical Perspectives-Medicni Perspektivi","volume":"92 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ways to promote the efficiency of herpetic stomatitis treatment\",\"authors\":\"R. Lutsenko, N. Moisieieva, A. Sydorenko, H.Yu. Ostrovska, A. A. Kapustianska\",\"doi\":\"10.26641/2307-0404.2023.2.283255\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The treatment of herpetic stomatitis should be etiotropic, pathogenetic, symptomatic, and local. The research determined the effectiveness of inosine pranobex (1000 mg 4 times a day) in herpetic stomatitis treatment. Addition of inosine pranobex to the pharmacotherapy of herpetic stomatitis reduced hospital stay and duration of treatment. The drug suppresses the synthesis of the virus due to the structure of inosinic acid in the polyribosomes of the cell affected by the virus, and also helps to eliminate the deficiency or dysfunction of immunity that occurred in the case of herpetic stomatitis, it affects the activity of T-cytotoxic lymphocytes and natural killers, enhances the action of neutrophil granulocytes, chemotaxis and phagocytosis of monocytes and macrophages, increases the synthesis of interleukins IL-1 and IL-2, affects the number of Ig G immunoglobulins. Applying inosine pranobex also significantly decreased pain syndrome manifestations from the start of the treatment. It contributed to body temperature normalization 2 days earlier which shortened the treatment period at the in-patient department. Applying inosine pranobex in the combination therapy of herpetic stomatitis has shown a potent clinical efficacy and can be an alternatіve to acyclic nucleosides in patients with herpetic stomatitis of the oral mucosa.\",\"PeriodicalId\":41059,\"journal\":{\"name\":\"Medical Perspectives-Medicni Perspektivi\",\"volume\":\"92 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Perspectives-Medicni Perspektivi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26641/2307-0404.2023.2.283255\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Perspectives-Medicni Perspektivi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26641/2307-0404.2023.2.283255","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

疱疹性口炎的治疗应是病因性的、病因性的、对症的和局部的。研究确定肌苷pranobex(1000毫克,每天4次)治疗疱疹性口炎的有效性。在疱疹性口炎的药物治疗中加入肌苷pranobex可减少住院时间和治疗时间。由于受病毒感染的细胞的多核糖体中肌苷酸的结构,该药抑制病毒的合成,也有助于消除疱疹性口炎病例中出现的免疫功能不足或功能障碍,影响t细胞毒性淋巴细胞和自然杀伤细胞的活性,增强中性粒细胞的作用,增强单核细胞和巨噬细胞的趋化和吞噬作用,增加白细胞介素IL-1和IL-2的合成。影响Ig G免疫球蛋白的数量。从治疗开始,肌氨酸pranobex也显著减少了疼痛综合征的表现。使患者体温提前2天恢复正常,缩短住院治疗时间。应用肌苷pranobex联合治疗疱疹性口炎已显示出强有力的临床疗效,可作为口腔粘膜疱疹性口炎患者的非环核苷类药物的替代药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ways to promote the efficiency of herpetic stomatitis treatment
The treatment of herpetic stomatitis should be etiotropic, pathogenetic, symptomatic, and local. The research determined the effectiveness of inosine pranobex (1000 mg 4 times a day) in herpetic stomatitis treatment. Addition of inosine pranobex to the pharmacotherapy of herpetic stomatitis reduced hospital stay and duration of treatment. The drug suppresses the synthesis of the virus due to the structure of inosinic acid in the polyribosomes of the cell affected by the virus, and also helps to eliminate the deficiency or dysfunction of immunity that occurred in the case of herpetic stomatitis, it affects the activity of T-cytotoxic lymphocytes and natural killers, enhances the action of neutrophil granulocytes, chemotaxis and phagocytosis of monocytes and macrophages, increases the synthesis of interleukins IL-1 and IL-2, affects the number of Ig G immunoglobulins. Applying inosine pranobex also significantly decreased pain syndrome manifestations from the start of the treatment. It contributed to body temperature normalization 2 days earlier which shortened the treatment period at the in-patient department. Applying inosine pranobex in the combination therapy of herpetic stomatitis has shown a potent clinical efficacy and can be an alternatіve to acyclic nucleosides in patients with herpetic stomatitis of the oral mucosa.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medical Perspectives-Medicni Perspektivi
Medical Perspectives-Medicni Perspektivi MEDICINE, GENERAL & INTERNAL-
CiteScore
0.40
自引率
0.00%
发文量
85
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信